Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
, 25 (7-8), 570-6

Efficacy of Reboxetine in Adults With Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled Clinical Trial

Affiliations
Randomized Controlled Trial

Efficacy of Reboxetine in Adults With Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled Clinical Trial

Forough Riahi et al. Hum Psychopharmacol.

Abstract

Objective: The main aim of this study is to evaluate the efficacy of reboxetine, a specific noradrenergic reuptake inhibitor, in adults with attention-deficit/hyperactivity disorder (ADHD).

Methods: In a double blind placebo-controlled clinical trial, the efficacy of 8 mg/day of reboxetine (twice daily) was compared with placebo in 40 adults diagnosed with ADHD during 6 weeks. The measures were Conners' Adult ADHD Rating Scale-Self-Report, Screening Version (CAARS-S, SV), Hamilton Anxiety and Depression Rating Scales, Clinical Global Impression - Severity Scale (CGI-S), and Global Assessment of Functioning Scale (GAF).

Results: There was a main effect of time and significant time X treatment (reboxetine vs. placebo) interaction on CAARS subscales and CGI scores which decreased along the study (p < 0.01). There was also a main effect of time and time X treatment interaction on GAF score which increased at the end point of the study (p < 0.01). In terms of Hamilton Anxiety and Depression Rating Scales there was just a main effect of time on Hamilton Depression Scale (p < 0.01). Irritability, anxiety, sleep disturbance, and dry mouth were the common side effects of reboxetine.

Conclusion: Reboxetine could be used and tolerated as an effective treatment for adults with ADHD.

Similar articles

See all similar articles

Cited by 6 PubMed Central articles

See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback